BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative Employers
  Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

Bristol-Myers Squibb Company 

38 Jackson Road

Devens  Massachusetts  01434  U.S.A.
Phone: n/a Fax: n/a


SEARCH JOBS



Bristol-Myers Squibb is a global biopharmaceutical company dedicated to helping patients prevail against serious disease.

We have delivered nine new products to patients in the last seven years for the treatment of psychiatric disorders, cancer, HIV, chronic hepatitis B and rheumatoid arthritis. We anticipate up to 6 additional regulatory approvals or submissions through 2012. In addition, scores of investigational medicines are advancing through our pharmaceutical development pipeline for such additional diseases as diabetes and cardiovascular disease, solid organ transplant rejection, Alzheimer's and obesity.

Bristol-Myers Squibb is recognized as having one of the most productive pipelines in the industry. Two of our marketed productive pipelines in the industry. Two of our marketed medicines and a number of investigational products are biologics. In the fight against serious disease, biologics - or protein-derived therapies - are playing an increasingly prominent role.

In our quest to help patients prevail, we are redefining our company and transforming ourselves for the future. By uniquely combining the strengths of a traditional pharmaceutical company with the attributes of a successful biotech company, we are becoming a new kind of enterprise, a next generation BioPharma. We are focused - agile and flexible, and infused with the entrepreneurial culture of an innovative biotech. Yet, at the same time, we are large enough to marshal the resources necessary to invest in our pipeline and bring new medicines to patients in need.

As a BioPharma leader, we are complementing and enhancing our internal capabilities with innovative alliances, partnerships and acquisitions. We call this our String of Pearls strategy.

Over the years, Bristol-Myers Squibb and its employees have received numerous distinguished awards and recognitions, including the National Medal of Technology and the Lasker Award for Medical Research. Recently, Bristol-Myers Squibb was included among Barron's 2009 Most Respected Companies Survey. Also, we've been hailed year after year as one of the best companies for working mothers and executive women, and as an acknowledged industry leader in environment, health, and safety management.



 Key Statistics


Email:
Ownership: Public

Web Site: Bristol-Myers Squibb Company
Employees:
Symbol: BMY
 









 Company News
Bristol-Myers Squibb Company (BMY) Announces Intention to Voluntarily Delist Preferred Stock 5/17/2013 9:50:13 AM    More...
Bristol-Myers Squibb Company (BMY) Advances Leadership Position in Immuno-Oncology with Data to be Presented at 2013 American Society of Clinical Oncology (ASCO) Annual Meeting 5/16/2013 8:47:01 AM    More...
Bristol-Myers Squibb Company (BMY) Drug Cocktail Stymies Melanoma Tumors 5/16/2013 7:32:59 AM    More...
Merck & Co., Inc. (MRK), Bristol-Myers Squibb Company (BMY) and Roche (RHHBY)'s Human Immune-Boosting Cancer Drugs Seen Extending Lives 5/13/2013 7:59:31 AM    More...
Adaptive Biotechnologies Signs Biomarker Discovery Collaboration Agreement With Bristol-Myers Squibb Company (BMY) 5/9/2013 10:02:30 AM    More...
Bristol-Myers Squibb Company (BMY), AstraZeneca PLC (AZN) Release: Sub-Group Analysis Shows Investigational Metreleptin Treatment Demonstrated Reductions in HbA1c, Triglycerides and Liver Function Tests in Pediatric Patients With Lipodystrophy During a 12-Month Period 5/6/2013 10:06:55 AM    More...
Bristol-Myers Squibb Company (BMY) Says FDA OKs Supplemental NDA for SUSTIVA 5/3/2013 7:24:14 AM    More...
Bristol-Myers Squibb Company (BMY) Partners Again With Ambrx, Inc. in Up to $112 Million and Up ADC Collaboration 5/3/2013 7:19:51 AM    More...
Bristol-Myers Squibb Company (BMY) Oral Hepatitis C Regimen Looks Competitive: Study 4/23/2013 7:57:04 AM    More...
Merck & Co., Inc. (MRK), Bristol-Myers Squibb Company (BMY) to Jointly Study Potential Hepatitis C Virus Drug 4/22/2013 7:33:04 AM    More...
12345678910...